Gregg Wagner, PhD
About Gregg Wagner, PhD
Gregg Wagner, PhD, is a Senior Manager in Regulatory Affairs at StrideBio, Inc., where he has worked since 2022. He has a strong background in clinical pharmacology and regulatory strategy, with previous roles at Metabolon, Inc. and Duke University.
Current Role in Regulatory Affairs
Gregg Wagner serves as the Senior Manager of Regulatory Affairs at StrideBio, Inc., a position he has held since 2022. In this role, he is responsible for overseeing regulatory strategies and ensuring compliance with industry standards. His expertise in regulatory affairs is complemented by his extensive background in scientific project management.
Experience at StrideBio, Inc.
Prior to his current role, Wagner worked at StrideBio, Inc. as a Senior Scientific Project Manager from 2019 to 2022. During this time, he managed the non-clinical study reporting and tracking process, ensuring that documentation was accurate and submitted in the eCTD format for Investigational New Drug (IND) applications. He also led the research for an Orphan Drug Designation application.
Educational Background
Wagner has a Doctor of Philosophy (Ph.D.) in Medical and Molecular Genetics from Indiana University School of Medicine, which he completed from 2008 to 2013. He also studied at Duke University Graduate School, where he participated in the Clinical Pharmacology-Clinical Research Training Program starting in 2014. Additionally, he attended Duke University's Fuqua School of Business, focusing on Biotech and Pharmaceutical Strategy in 2015.
Previous Positions and Research Experience
Before joining StrideBio, Wagner held various positions in research and project management. He worked as a Senior Study Director at Metabolon, Inc. from 2018 to 2019 and as a Study Director from 2016 to 2018. He also served as a Postdoctoral Research Fellow at Duke University from 2013 to 2016 and as a Scholar in Endocrinology and Metabolism at Duke University from 2014 to 2015.
Skills in Project Management and Collaboration
Wagner has demonstrated strong project management skills throughout his career. He has strategized program regulatory plans in collaboration with external consultants in chemistry, manufacturing, and controls (CMC), as well as non-clinical and clinical areas. His ability to collaborate cross-functionally has been essential in aligning internal processes with FDA feedback.